New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9, A Genetically Validated Regulator Of LDL Metabolism
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that new pre-clinical data from its hypercholesterolemia program was published in Proceedings of the National Academy of Sciences (Frank-Kamenetsky, M., et al (August 11, 2008) Proc. Natl Acad. Sci. USA, 10.1073/pnas.0805434105).
More: continued here
Filed under: Cholesterol on September 8th, 2008